QSAM Biosciences Inc. announced that the European Patent Office (EPO) has allowed a key patent that protects the use of “lower specific activity” Samarium-153 in conjunction with the treatment of bone cancer in children and adults. This new patent in Europe covers the “high purity therapeutic bone agents” technology exclusively licensed to QSAM on a worldwide basis and relates to the novel manner in which the Samarium-153 is produced for use in CycloSam®. In addition to providing streamlined manufacturing, lower costs and logistical advantages, that process significantly reduces long-lived impurities, namely Europium-154, which may allow for higher and multiple dosing regimens in the treatment of different types of bone cancer, including cancer that has metastasized from the breast, lung, prostate, kidney or other organs.

These types of metastasized bone cancer are the subject of QSAM's current FDA-cleared Phase 1 clinical trial which is underway and actively enrolling and dosing patients.